ReviewClinical chemistry2014
Noninvasive micromarkers.
Review in Clinical chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Advanced Diagnostic Technologies and Molecular Biomarkers in Periodontitis: Systemic Health Implications and Translational Perspectives.Journal of clinical medicine · 2026Review
- Roles of microRNAs in cardiorenal syndrome.Molecular and cellular biochemistry · 2025Review
- Anti-inflammatory effects of miRNA-146a induced in adipose and periodontal tissues.Biochemistry and biophysics reports · 2020Article
- miR-451 Loaded Exosomes Are Released by the Renal Cells in Response to Injury and Associated With Reduced Kidney Function in Human.Frontiers in physiology · 2020Article
- Reliability of miRNA Analysis from Fixed and Paraffin-Embedded Tissues.International journal of molecular sciences · 2019Article
- MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update.FASEB bioAdvances · 2019Article
- Urinary miR-21 as a potential biomarker of hypertensive kidney injury and fibrosis.Scientific reports · 2017Article
- A more tubulocentric view of diabetic kidney disease.Journal of nephrology · 2017Review
- Urinary Biomarkers for Chronic Kidney Disease with a Focus on Gene Transcript.Chinese medical journal · 2017Review
- Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy.Clinical chemistry · 2017Article
- Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy.Chemical science · 2017Article
- MicroRNAs in injury and repair.Archives of toxicology · 2017Review
- Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR.Journal of visualized experiments : JoVE · 2017Article
- Elevated circulating miR-126-3p expression in patients with acute myocardial infarction: its diagnostic value.International journal of clinical and experimental pathology · 2017Article
- Inflammation-related microRNA expression level in the bovine milk is affected by mastitis.PloS one · 2017Article
- Absolute Measurement of Cardiac Injury-Induced microRNAs in Biofluids across Multiple Test Sites.Toxicological sciences : an official journal of the Society of Toxicology · 2016Article
- Circulating RNAs as new biomarkers for detecting pancreatic cancer.World journal of gastroenterology · 2015Review
- Article
- MicroRNAs in kidney physiology and disease.Nature reviews. Nephrology · 2015Review
- A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe recent revolutionary advances made in genome-wide sequencing technology have transformed biology and molecular diagnostics, allowing new sRNA (small RNA) classes to be discovered as potential disease-specific biological indicators. Cell-free microRNAs (miRNAs) have been shown to exist stably in a wide spectrum of body fluids and their expression profiles have been shown to reflect an assortment of physiological conditions, underscoring the utility of this new class of molecules to function as noninvasive biomarkers of disease. CONTENT: We summarize information on the known mechanisms of miRNA protection and release into extracellular space and compile the current literature on extracellular miRNAs that have been investigated as biomarkers of 20 different cancers, 11 organ damage conditions and 10 diverse disease states. We also discuss the various strategies involved in the miRNA biomarker discovery workflow and provide a critical opinion on the impediments faced by this advancing field that need to be overcome in the laboratory. SUMMARY: The field of miRNA-centered diagnostics is still in its infancy, and basic questions with regard to the exact role of miRNAs in the pathophysiology of diseases, and the mechanisms of their release from affected cells into biological fluids are yet to be completely understood. Nevertheless, these noninvasive micromarkers have immense potential in translational medicine not only for use in monitoring the efficacy and safety of therapeutic regimens but also to guide the diagnosis of diseases, to determine the risk of developing diseases or conditions, and more importantly, to inform treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.